Physiomics PLC Collaboration with The University of Sheffield
31 May 2023 - 4:00PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
31 May 2023
31 May 2023
Physiomics plc
("Physiomics" or the "Company")
Collaboration with The University of Sheffield
Physiomics plc (AIM: PYC), a leading mathematical modelling
company supporting oncology drug development and personalised
medicine solutions, is pleased to announce that it is supporting
The University of Sheffield (the "University") with research into
an insect (Drosophila melanogaster) model of cancer treatment that
could be used to screen potential new drugs prior to pre-clinical
testing in more traditional mouse models of cancer. This new
approach could provide important insights into the development of
new cancer therapies as well as potentially reduce the number of
pre-clinical animals involved in the drug development process.
Principal investigator Dr Kyra Campbell of the University is the
beneficiary of a three-year grant from the National Centre for the
Replacement, Refinement and Reduction of Animals in Research
(NC3Rs), awarded in December 2021, which has funded a significant
programme of research at the University and other institutions
where her co-investigators are based.
The University successfully applied for funding under the UK
Research and Innovation (UKRI) Higher Education Innovation Funding
(HEIF) scheme, part of which will be used to retain Physiomics for
a pilot project to analyse data generated by its innovative new
testing platform in order to better understand how the platform
might guide later stages of pharmaceutical research into cancer
therapies, including pre-clinical and human studies.
The project is expected to be concluded over the next two
months, and a longer-term collaboration is currently under
discussion.
Physiomics CEO, Dr Jim Millen commented :
"We are delighted to have been selected by The University of
Sheffield to support this highly innovative research program with
our analytical and modelling capabilities. We look forward to
working with Dr Campbell and her colleagues and believe that both
our analytical capabilities, as well as our contacts and experience
within the pharmaceutical industry, could add real value to the
initiative."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in
order to de-risk decision making and optimise design of
pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour
technology, the Physiomics team has informed the development of
over 100 projects, over 50 targets and 75 drugs. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAURSVROUUVOAR
(END) Dow Jones Newswires
May 31, 2023 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024